Compare Shanghai Pharmaceuticals Holding Co., Ltd. with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 0.65% of over the last 5 years
- The company is Net-Debt Free
2
Flat results in Dec 19
3
With ROE of 8.93%, it has a Very Expensive valuation with a 0.79 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
HKD 10,781 Million ()
9.00
NA
0.00%
0.17
8.66%
0.12
Revenue and Profits:
Net Sales:
84,927 Million
(Quarterly Results - Mar 2026)
Net Profit:
2,088 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0.26%
0%
0.26%
1 Year
3.99%
0%
3.99%
2 Years
-2.41%
0%
-2.41%
3 Years
-25.67%
0%
-25.67%
4 Years
-8.93%
0%
-8.93%
5 Years
-28.65%
0%
-28.65%
Shanghai Pharmaceuticals Holding Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.97%
EBIT Growth (5y)
0.65%
EBIT to Interest (avg)
4.71
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
2.17
Tax Ratio
29.24%
Dividend Payout Ratio
28.80%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
10.03%
ROE (avg)
10.26%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.79
EV to EBIT
10.97
EV to EBITDA
8.40
EV to Capital Employed
0.82
EV to Sales
0.27
PEG Ratio
0.26
Dividend Yield
NA
ROCE (Latest)
7.50%
ROE (Latest)
8.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Dec 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
84,927.40
75,147.10
13.01%
Operating Profit (PBDIT) excl Other Income
2,760.00
2,782.10
-0.79%
Interest
392.30
444.50
-11.74%
Exceptional Items
69.30
240.20
-71.15%
Consolidate Net Profit
2,087.70
1,083.30
92.72%
Operating Profit Margin (Excl OI)
32.50%
25.40%
0.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 13.01% vs -6.41% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 92.72% vs 0.00% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
306,982.70
297,900.20
3.05%
Operating Profit (PBDIT) excl Other Income
12,136.80
12,260.00
-1.00%
Interest
1,988.40
2,150.30
-7.53%
Exceptional Items
-793.30
-348.50
-127.63%
Consolidate Net Profit
7,563.20
6,364.40
18.84%
Operating Profit Margin (Excl OI)
28.80%
31.70%
-0.29%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.05% vs 3.87% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 18.84% vs 11.48% in Dec 2024
About Shanghai Pharmaceuticals Holding Co., Ltd. 
Shanghai Pharmaceuticals Holding Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






